PMC Group Inc. Overview
PMC Group is a founder-owned, acquisition-built US specialty chemicals and pharmaceutical-manufacturing conglomerate headquartered in Mount Laurel, New Jersey. Since 1994 it has assembled more than twenty carve-outs from global chemical majors – including PPG, BASF, ExxonMobil, ICI, Nova Chemicals, Chemtura, Arkema, Dow, AkzoNobel and Lanxess – typically acquiring non-core, mature niche product lines and repositioning them under PMC brands. Today the group describes itself as a global manufacturer of intermediate chemicals for industrial and specialty markets [S1], organized into nine business units: organotin stabilizers and catalysts (PMC Organometallix), renewable-based oleochemical derivatives (PMC Biogenix), defoamers and wax emulsions (PMC Crystal), flame-retardant and additive masterbatches (PMC Polymer Products), specialty esters (PMC Ouvrie), rubber chemicals in India, pharmaceutical CDMO services in France (PMC Isochem) and India, and nitroglycerin/energetic materials (Copperhead Chemical). Its competitive model rests on niche leadership, owner-operator decision speed and opportunistic portfolio rotation rather than scale.
Company's own description
On its current website, PMC Group characterizes itself as a global manufacturer of intermediate chemicals serving a broad range of industrial and specialty markets, emphasizing technical expertise, operational reliability, consistent quality and dependable supply; its tagline is "Technical Expertise. Reliable Supply. Proven Performance." [S1]. Earlier press-release boilerplate (2019–2021) described PMC as a US-based, growth-oriented, diversified global chemicals and pharmaceuticals company serving plastics, consumer products, electronics, coatings, packaging, mining, personal care, food, automotive and pharmaceuticals, built on growth through innovation while promoting social good [S3][S8]. The April 2026 boilerplate adds that PMC sources over half of its raw materials from renewable feedstocks [S19].
The shift in self-description – from "growth-oriented diversified chemicals and pharmaceuticals company" (2019–2021) to "global manufacturer of intermediate chemicals" with a reliability-of-supply message (2025–2026) – is analytically meaningful: it coincides with retrenchment (Memphis closure, exit from commodity fatty acids) and a website redesign, and suggests management is emphasizing supply security and operational dependability over expansionary diversification.
Independent characterization
PMC Group is best understood as a private, family-controlled roll-up of corporate carve-outs in mature, niche chemistries. The business model has three recurring features:
-
Carve-out acquisition from majors. Of the 24 dated milestones on the company's history page, 20 are acquisitions, and almost all are divisions divested by large multinationals (BASF ×3, Arkema ×2, PPG, ExxonMobil, ICI, Nova, Chemtura, Dow, AkzoNobel, Lanxess, Ecolab, Nexen, Isochem/Aurelius) [S2]. Purchase prices have consistently been undisclosed.
-
Niche concentration. Several units occupy small, consolidated global markets: organotin PVC heat stabilizers and tin catalysts (where the 2012–2013 Arkema and Dow deals gave PMC "a large share" of the world tin PVC stabilizer market, per the International Tin Association [S11]); fatty primary amides (Armoslip®, Kemamide®); and pharmaceutical-grade nitroglycerin, where Copperhead has been described as the sole US manufacturer of FDA-approved nitroglycerin for over 70 years [S8][S9].
-
Asset rationalization after acquisition. PMC routinely restructures acquired footprints – e.g., relocating Lanxess organotin production from Bergkamen, Germany to Axis, Alabama and Carrollton, Kentucky (2020–2022) [S10], and closing the legacy Memphis oleochemicals plant (April 2026) after shifting amide capacity to South Korea [S12][S16].
Revenue model
| Revenue type | Share of revenue | Description |
|---|---|---|
| Product sales (specialty/intermediate chemicals) | Not publicly disclosed (assessed as the large majority) | Organotin stabilizers/catalysts, fatty amides/esters, metallic stearates, defoamers, wax emulsions, masterbatches, specialty esters, rubber chemicals |
| Pharmaceutical products (APIs, intermediates, excipients, bulk drug substance) | — | PMC Isochem (France), PMC YM-Pharma / PMC Pharmaceuticals India, Copperhead (nitroglycerin bulk drug substance listed with FDA as bulk ingredient [S26][S27]) |
| Contract/custom manufacturing services (CDMO) | — | Custom synthesis, process development, scale-up at PMC Isochem; custom dosage-form manufacturing at Copperhead [S6][S9] |
| Defense energetic materials | — | Copperhead supplies energetic chemicals (explosives and propellants) to the defense sector [S8][S31] |
| Licensing / subscription | None disclosed | — |
Value-chain position
PMC sits in the mid-stream intermediate and additive layer: it buys tin metal, fatty acids/oils, glycerin, petroleum waxes and basic chemicals, and sells performance additives and intermediates to compounders, formulators, converters and drug manufacturers. Its products are typically low-percentage-by-weight but performance-critical inputs (heat stabilizers in rigid PVC, slip agents in polyolefin film, catalysts in coatings and urethanes, defoamers in food processing). This position confers pricing power when supply is concentrated (evidenced by the 10–25% across-the-board price increase announced by PMC Organometallix in April 2026 [S19]) but exposure to raw-material swings (tin, fatty-acid feedstocks) and to substitution and regulatory risk.
Customer types and end-markets
| End-market | Primary PMC units serving it | Example products |
|---|---|---|
| Plastics / PVC (building & construction, packaging) | Organometallix, Biogenix, Polymer Products | Organotin heat stabilizers; Armoslip®/Kemamide® slip and anti-block amides; flame-retardant masterbatches |
| Coatings, inks, adhesives | Organometallix, Crystal | FASCAT® tin catalysts; CrystalCer® wax emulsions [S20][S25] |
| Food processing & fermentation | Crystal, Ouvrie | Food/fermentation defoamers (ex-BASF business) [S2] |
| Rubber / tires | PMC Rubber Chemicals (India), Crystal | Accelerators, antioxidants, antiozonants, antiozonant waxes [S21] |
| Electronics & wire/cable | Crystal, Polymer Products | Cable-filling compounds, antistatic masterbatches [S5][S21] |
| Personal care & consumer products | Biogenix, Ouvrie | Glycerol esters, specialty esters [S12] |
| Pharmaceuticals | Isochem, YM-Pharma/PMC Pharmaceuticals India, Copperhead | APIs, intermediates, excipients, NCA/polyamino acids, bulk nitroglycerin [S6][S7][S9] |
| Defense | Copperhead | Energetic materials for propellants and munitions (business-level description only) [S8][S31] |
| Mining, automotive | Group-wide | Cited in boilerplate [S3][S19] |
Strategy
Stated strategic themes
PMC publishes no annual report or investor day. Recurring strategic themes from press releases and the website are:
-
Growth through acquisition of niche specialty businesses, with the 2008 statement that the group's growth strategy centered on specialty chemicals and engineered resins [S5].
-
Commitment to the organotin industry and to being customers' preferred organotin supplier, backed by capacity investment [S4][S10].
-
Building an end-to-end pharma CDMO spanning all phases of drug development and manufacturing across three continents (US, Europe, India) [S8].
-
Higher-value focus in oleochemicals, exiting commodity fatty acids [S12].
-
Reliability of supply and technical expertise as the 2025–2026 brand promise [S1].
-
Sustainability via renewable feedstocks – over half of raw materials from renewable sources [S19] – and "growth through innovation while promoting social good" [S3].
Strategic initiatives – last 24 months (Oct 2024 – Oct 2026)
| Initiative | Date | Type | Detail | Source |
|---|---|---|---|---|
| Gyeongju Armoslip® expansion | Construction from late 2024; supply by mid-2026 | Capacity investment | +50% production capacity for fatty amides | [S12] |
| Memphis restructuring and closure | Product review 2024; WARN Feb 2026; closure 26 Apr 2026 | Restructuring / footprint consolidation | Exit commodity bulk fatty acids; then full closure, 172 jobs | [S12][S16] |
| Organometallix global price increase | Announced 24 Apr 2026; effective 1 May 2026 | Commercial / pricing | +10–25% on all product lines globally | [S19] |
| Corporate rebrand and website relaunch | 2025–2026 | Brand | New BU logos; "Chemistry that powers performance" messaging | [S1] |
Earlier strategic programs still shaping the portfolio
| Initiative | Date | Detail | Source |
|---|---|---|---|
| Organotin US capacity expansion | 2020–early 2022 | Axis, AL (intermediates) and Carrollton, KY (catalysts), relocating Bergkamen production | [S10] |
| Pharma platform build | 2017–2021 | YM-Pharma, Isochem, Copperhead | [S6][S7][S8] |
| Africa distribution | Jun 2021 | Safic-Alcan exclusive/authorized distribution for FASCAT® | [S15] |
Medium-term financial targets / guidance
Not publicly disclosed. PMC issues no financial guidance.
Products & Services
Pricing models are not publicly disclosed for any product line; PMC sells on contract and spot terms, and has used across-the-board percentage price increases (Biogenix Nov 2020 [S13]; Organometallix +10–25% from May 2026 [S19]).
PMC Organometallix (organotin chemistry)
| Product line | Description / capabilities | Target customers | Origin / latest disclosed date | Flagship |
|---|---|---|---|---|
| Organotin PVC heat stabilizers (methyl tin and other organotins) | Thermal stabilization of rigid PVC during processing (pipe, profile, sheet, packaging) | PVC compounders and converters | Arkema (2012), Dow methyl tin (2013) [S11] | Brand names not confirmed in sources reviewed |
| Heavy-metal-free organic polymer stabilizers | Non-tin, non-heavy-metal stabilizer systems | PVC processors seeking regulatory-compliant alternatives | Dow (2013) [S11] | — |
| Polymer lubricants / solid lubricants & multi-component one-pack systems | Processing lubricants combined with stabilizers | PVC processors | Dow (2013) [S11] | — |
| FASCAT® organotin catalysts | Selective catalysts for esterification, transesterification, urethane and siloxane condensation; lower reaction temperatures and faster rates; used in coatings and e-coat curing | Coatings, polyester resin, urethane, silicone producers | Arkema (2012); expanded by Lanxess line (2019); Carrollton capacity expansion 2020–2022 [S10][S25] | FASCAT® 4102 (butyltin tris-2-ethylhexanoate, hydrolytically stable) [S20] |
| Organotin specialties & intermediates (ex-Lanxess) | Global organotin catalyst, specialty and intermediate lines | Downstream organotin and catalyst users | Lanxess, closed Dec 2019 [S3] | — |
| Tin intermediates / fine chemicals & reagents | Organotin intermediates (expanded at Axis, AL) and reagents | Chemical and fine-chemical manufacturers | 2020–2022 expansion [S10] | — |
| Organophosphine-based products | Organophosphine stabilizers/fine chemicals | Specialty users | Arkema (2012) [S11] | — |
Note: ChemPoint lists 84 PMC Organometallix products in its plastics catalogue and describes the Carrollton, KY site as a 400-acre facility [S25].
PMC Biogenix (renewable oleochemical derivatives)
| Product line | Description | Target customers | Status | Flagship |
|---|---|---|---|---|
| Fatty amides and bisamides | Slip, anti-block, release and lubricant additives for polyolefin films and plastics | Film and packaging converters, compounders | Core focus post-2024; Gyeongju capacity +50% targeted mid-2026 [S12] | Armoslip® (ex-AkzoNobel, 2013), Kemamide® (ex-Chemtura, 2008) |
| Glycerol esters | Antistatic/anti-fog and emulsifier applications | Plastics, food, personal care | Retained core [S12] | Kemester® |
| Specialty esters | Lubricants, emollients, processing aids | Personal care, industrial | Retained core [S12] | Kemester® |
| Metallic stearates | Acid scavengers, lubricants, release agents | Plastics, rubber | Retained core [S12] | Lubrazinc® |
| Merchant commodity bulk fatty acids | Bulk fatty acids sold to third parties | Industrial | Exited (announced June 2024) [S12] | — |
| Glycerin, process acids | By-products/derivatives of oleochemical processing | Industrial | Historically listed [S21] | — |
PMC Crystal (Lansdale, PA)
| Product line | Description | Target customers | Origin | Flagship |
|---|---|---|---|---|
| Specialty antifoams & defoamers | Foam control for industrial and food/fermentation processes | Food processors, fermentation, paper, coatings | Crystal Soap (1995); BASF food & fermentation defoamers (2012) [S2][S5] | — |
| Wax emulsions | Water resistance, dust control, slip and lubricity | Inks, coatings, corrugated box coatings | ExxonMobil wax emulsions (2005) [S2][S20] | CrystalCer® C (acid-sensitive paraffin emulsion); CrystalCer® 90 (anionic, acid-stable) [S20] |
| Metallic stearates | Lubricants/release agents | Rubber, plastics | Crystal [S5] | — |
| Rubber & plastic processing aids | Processing aids | Rubber/plastics compounders | Crystal [S5] | — |
| Cable filling compounds | Water-blocking gels for cables | Wire & cable makers | Crystal [S5] | — |
| Specialty petrolatum & waxes | Specialty wax products | Industrial, rubber (antiozonant waxes) | Crystal [S5][S21] | — |
PMC Polymer Products (Stockertown, PA)
| Product line | Description | Target customers | Origin |
|---|---|---|---|
| Flame-retardant masterbatches & compounds | Design and development of flame-retardant additive concentrates | Plastics compounders, electronics, building products | PPG Polymer Products (1994) [S2][S5] |
| Additive masterbatches (incl. antistatic) | Custom additive concentrates | Film and molded-part producers | [S5][S21] |
| Ignition-resistant polyolefins & styrenics | Ignition-resistant polystyrene (Avantra®, ex-BASF 2000; Zyntar®, ex-Nova 2006) | Electronics housings, appliances | [S2][S21] (current commercial status of Avantra®/Zyntar® brands not confirmed) |
PMC Ouvrie (Lesquin, France)
| Product line | Description | Target customers | Origin |
|---|---|---|---|
| Specialty esters | Esters for multiple applications | Industrial, personal care, food | BASF Ouvrie (1999); Delchim/Sacap (2003) [S2][S5] |
| Defoamers | Process foam control | Food and general industry | [S5][S9] |
| Surfactants & protective colloids | Formulation aids | Food and general industrial | [S9] |
PMC Rubber Chemicals (India)
| Product line | Description | Target customers | Origin |
|---|---|---|---|
| Accelerators | Vulcanization accelerators | Tire and rubber goods makers | ICI India rubber chemicals (2005) [S2][S21] |
| Antioxidants & antiozonants | Rubber protection chemicals | Tire and rubber goods makers | [S21] |
PMC Isochem (France)
| Offering | Description | Target customers | Notes |
|---|---|---|---|
| Custom synthesis / CDMO | Research, process development, regulatory support, pilot and full-scale production of intermediates and APIs | Major pharma companies (oncology, cardiovascular, infectious, GI, neurology, rare diseases) | Acquired Dec 2017 [S6][S30] |
| Excipients & APIs | Manufacture of excipients and active ingredients | Pharma, cosmetics | ~50 years' experience; ~250 staff across 3 sites (2025) [S23] |
| Specialty chemistries | Phosgene chemistry (Vert-le-Petit); fractional distillation (Gennevilliers); pressure hydrogenation and waste processing (Pithiviers) | Pharma/fine chemicals | [S22] |
| ISODEL® drug delivery | NCA (N-carboxyanhydride) and polyamino acid (PAA) "one-stop shop" for drug delivery | Drug-delivery developers | Trade-press headlines; undated in sources [S35] |
| Protein engineering, drug development & discovery services | Service offerings cited by PMC in 2021 | Biotech/pharma | [S8] |
PMC Pharmaceuticals India / PMC YM-Pharma (Hyderabad)
| Offering | Description | Target customers | Notes |
|---|---|---|---|
| Fluoroquinolone APIs | cGMP plant described as one of India's largest fluoroquinolone manufacturers; zero-discharge effluent system | Generic drug makers | Acquired 2017 [S7] |
| Generic APIs & intermediates (expansion focus) | Oncology, neuropsychiatry, GI, pulmonary hypertension, anti-depressant, anti-migraine | Global generics market | Stated 2017 ambition [S7] |
| Process development | Advanced pharmaceutical intermediate manufacturing | Pharma | [S8] |
Copperhead Chemical (Tamaqua, PA)
| Offering | Description | Target customers | Notes |
|---|---|---|---|
| Pharmaceutical-grade nitroglycerin (diluted, bulk ingredient) | FDA-listed bulk drug substance supplied for further manufacturing; multiple NDC package codes active in 2026 | Cardiovascular drug manufacturers, compounders | Described as sole US maker of FDA-approved nitroglycerin for 70+ years [S8][S26][S27] |
| Other DMF-listed bulk substances | PharmaCompass lists DMF entries including SDM-78 (US DMF and Japanese DMF) | Pharma | [S27] |
| Custom dosage-form manufacturing | Custom manufacturing of drug dosage forms | Pharma | [S9] |
| Energetic materials for defense | Nitrate-ester-based energetic chemicals for propellants and munitions (business-level description only) | US defense primes (e.g., Northrop Grumman award, 2022) | [S8][S31][S33] |
| Preservatives & antimicrobials | A "novel class" of preservatives and antimicrobials | Pharma/industrial | [S8] |
| Technical & analytical services | Material analyses, test-method development, instrument calibration | Defense/pharma | [S31] |
Financial Narrative
Disclosure status: PMC Group, Inc. does not publish consolidated financial statements. No revenue, profit, balance-sheet, cash-flow or ratio data for the group has been publicly disclosed in any source reviewed. Third-party "estimated revenue" figures returned by web searches for "PMC Group" relate to unrelated companies (see disambiguation) and are excluded. All values below are therefore NA (not publicly disclosed).
Income statement
Revenue CAGR FY2021–FY2025: not publicly disclosed.
Commentary on trends, inflections and drivers (qualitative, evidence-based)
Even without disclosed financials, the public record allows several directional inferences about PMC's financial trajectory over FY2021–FY2026:
Revenue drivers. FY2021–FY2022 likely benefited from the global post-pandemic specialty-chemicals pricing cycle and from the full-year consolidation of Copperhead (acquired February 2021) and the ex-Lanxess organotin line (closed December 2019) as Bergkamen volumes were relocated to US sites during 2020–early 2022 [S8][S10]. Peer evidence from listed tin-chemicals competitor Songwon indicates that 2025 was a soft year for the industry: Songwon's consolidated sales fell 2.9% to KRW 1,039,162M, with its tin intermediates business citing weak demand, intensified competition, declining prices and European logistics issues during 2025 [S28]. PMC's organotin business, exposed to the same PVC and coatings demand, is likely to have faced similar pressure in 2025.
Margin and restructuring inflection. The June 2024 Biogenix announcement explicitly framed the Memphis product review and exit from merchant commodity fatty acids as a move to improve operational efficiency and focus on higher-value amides and esters [S12]. The subsequent full closure of Memphis in April 2026 [S16] implies one-time restructuring charges (severance for 172 employees, decommissioning, potential environmental remediation) in FY2025–FY2026, offset over time by fixed-cost removal and mix improvement.
Pricing as a 2026 lever. The 10–25% global price increase across all Organometallix product lines effective May 2026 [S19] signals both cost inflation (tin, freight, logistics) and confidence in pricing power. Its realization will be a key determinant of FY2026 margins.
Capital intensity. Disclosed capex programs over the period include: the Axis, AL and Carrollton, KY organotin expansions (2020–early 2022) [S10]; the Gyeongju, South Korea Armoslip® expansion (construction from late 2024, +50% capacity, supply by mid-2026) [S12]; and an R&D investment of EUR 2M at PMC Isochem (undated trade headline) [S35]. Amounts for the US and Korean projects were not disclosed.
Financing. PMC's acquisitions have historically been financed privately, with terms undisclosed; the 2008 Chemtura deal was explicitly "subject to financing" [S5], indicating use of acquisition debt. Lender identities, facility sizes and covenants are not publicly disclosed.
Unlock Company Financials
Unlock this company profile to view its financial data.
View Subscription PlansFinancial Detail
Holding Arm Details
| Holding arm | Description | Units / subsidiaries (disclosed) |
|---|---|---|
PMC Group N.A., Inc. | North American specialty chemicals holding company; President Debtosh Chakrabarti | PMC Organometallix, Inc.; PMC Biogenix, Inc.; PMC Crystal; PMC Polymer Products |
PMC Group International, Inc. | Described as an "independent arm" of PMC Group; President Dr. Raj Chakrabarti | PMC Group France (→ PMC Ouvrie; PMC Isochem SAS; India rubber chemicals acquired via PMC France); PMC YM-Pharma Private Ltd. (India); Cobra Investments Management Inc. → Copperhead Chemical Company Inc., Copperhead Investments Inc. |
Real estate & technology | Group service entities | PMC Real Estate, LLC (HQ building); PMC Advanced Technology, LLC (launched 2010) |
Business Units
| Business unit | Company's tagline (paraphrased) | Core chemistry | Primary site(s) |
|---|---|---|---|
PMC Crystal | Innovation as cornerstone | Defoamers, wax emulsions, metallic stearates, processing aids, cable filling compounds | Lansdale, PA |
PMC Biogenix | Global producer of renewable-based chemicals | Fatty amides/bisamides, glycerol esters, metallic stearates, specialty esters | Gyeongju, South Korea (Memphis closed Apr 2026) |
PMC Polymer Products | Innovation-driven | Additive masterbatches, flame-retardant compounds | Stockertown, PA |
PMC Organometallix | Specialized stabilizers | Organotin PVC stabilizers, FASCAT® catalysts, tin intermediates, reagents | Carrollton, KY; Netherlands |
PMC Rubber Chemicals | Developer/producer of rubber chemicals | Accelerators, antioxidants, antiozonants | India |
PMC Pharmaceuticals India Private Limited | Custom pharmaceutical manufacturing | APIs and intermediates | India (believed to be the ex-YM-Pharma Hyderabad operation; renaming not independently confirmed) |
PMC Isochem | Custom pharmaceutical manufacturing | APIs, intermediates, excipients; phosgene, hydrogenation and distillation chemistry | Vert-le-Petit, Gennevilliers, Pithiviers (France) |
PMC Ouvrie | Specialty esters | Specialty esters, defoamers, surfactants, protective colloids | Lesquin, France |
Copperhead Chemical | Energetic materials | Pharmaceutical-grade nitroglycerin; nitrate-ester energetics for defense | Tamaqua, PA |
Analytical Segment Details
| Analytical segment | Units |
|---|---|
A. Polymer & Performance Additives | Organometallix, Biogenix, Polymer Products, Crystal, Rubber Chemicals |
B. Specialty Esters & Food/Industrial Process Aids | Ouvrie, Crystal (food defoamers) |
C. Pharma & Energetics (PMC Group International) | Isochem, PMC Pharmaceuticals India / YM-Pharma, Copperhead |
Segment revenue (USD Mn) | FY2023 |
Segment operating income (USD Mn) | FY2023 |
Segment operating margin (%) | FY2023 |
Financial Analysis
| Metric | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
Margin | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
Data Point Details
| Data point | Value | Period | Reliability |
|---|---|---|---|
PMC Isochem headcount | ~250 employees across 3 French sites | April 2025 | Company job posting – reliable |
PMC Isochem headcount at acquisition | 230+ employees | Dec 2017 | Press release – reliable |
Chemtura oleochemicals headcount at acquisition | ~275 employees | Feb 2008 | Company spokesperson – reliable |
PMC Biogenix Memphis headcount at closure | 172 (122 union-represented) | Feb–Mar 2026 | WARN notice – reliable |
PMC Isochem financials (French INPI filings via aggregator) | Aggregator shows personnel costs of roughly EUR 17–18M per year (2021–2024) alongside an internally inconsistent revenue figure (~EUR 11.0M for 2021) and gross-margin series | 2021–2024 | Unreliable/conflicting – figures do not reconcile (a ~250-person API manufacturer with EUR 17–18M personnel cost is inconsistent with EUR 11M revenue); not used for analysis. Primary filings at Infogreffe/INPI should be consulted |
Region revenue (USD Mn)
| Region revenue (USD Mn) | FY2023 | FY2024 | FY2025 |
|---|---|---|---|
Region revenue growth (%) | FY2023 | FY2024 | FY2025 |
Business Units by Unit
| Unit | USA | France | Netherlands | India | South Korea |
|---|---|---|---|---|---|
Organometallix | Carrollton, KY (production) | — | Production/commercial presence | — | — |
Biogenix | Memphis, TN (closed Apr 2026) | — | — | — | Gyeongju (production; expanding) |
Crystal | Lansdale, PA | — | — | — | — |
Polymer Products | Stockertown, PA | — | — | — | — |
Copperhead | Tamaqua, PA | — | — | — | — |
Ouvrie | — | Lesquin | — | — | — |
Isochem | — | Vert-le-Petit, Gennevilliers, Pithiviers | — | — | — |
Rubber Chemicals | — | — | — | Production | — |
PMC Pharmaceuticals India / YM-Pharma | — | — | — | Hyderabad | — |
Share price performance (%)
| Share price performance (%) | FY2023 |
|---|---|
Item | Status |
1/3/5-year share price performance | Not applicable (private) |
Moody's / S&P / Fitch ratings | None identified |
Peer valuation context | Listed peers (SONGWON, NOCIL, Croda) provide reference points for any private valuation; SONGWON's FY2025 net profit of only KRW 2,296M (preliminary) on ~KRW 1.04 trillion sales illustrates thin profitability in tin and stabilizer chemistry in 2025 [S28][S36] |
Analyst Conclusions
Management guidance and consensus
Management guidance: not publicly disclosed. Consensus expectations: none (no analyst coverage). Directional signals from management actions in 2024–2026 are (i) capacity growth in Korean fatty amides, (ii) footprint rationalization in the US oleochemicals business, and (iii) aggressive price recovery in organotins.
Bull case (grounded in evidence)
-
Pricing plus niche concentration lifts margins. A 10–25% across-the-board organotin price increase effective May 2026 [S19], in a market where PMC holds a large global share [S11], could materially expand FY2026–FY2027 margins if retained.
-
Restructuring dividend. Exiting commodity fatty acids and closing Memphis [S12][S16], while adding 50% amide capacity in Korea [S12], should structurally improve Biogenix mix and fixed-cost absorption from 2H 2026.
-
Strategic pharma/defense assets gain value. Copperhead's sole-US nitroglycerin status [S8] and defense-supplier recognition [S33] align with onshoring and munitions-demand trends, potentially making it the group's most valuable asset per dollar of revenue.
Bear case (grounded in evidence)
-
Structural decline in tin chemistry. Peer data show 2025 weakness in tin intermediates with falling prices and intensified competition [S28]; price increases may accelerate substitution or share loss.
-
Hazard and EHS tail risk. Phosgene and nitration chemistries plus a history of a 2014 EPA penalty and a 2022 plant incident [S17][S24] create low-probability, high-severity exposure.
-
Opacity and concentration. With no published financials, unknown leverage and founder-centric governance [S14], counterparties cannot assess solvency; succession uncertainty could disrupt a portfolio that depends on owner-led deal-making.
Key catalysts and monitorables (next 12 months)
| Monitorable | Why it matters | Indicator |
|---|---|---|
| Gyeongju ramp confirmation | Validates Biogenix pivot | Company announcement or customer supply notices |
| Price-increase realization (Organometallix) | Margin driver | Follow-on announcements; distributor price lists |
| Memphis site disposition/remediation | Liability and asset-sale potential | Local filings, property transactions |
| Copperhead defense contracts/capacity | Growth in energetics | Prime-contractor supplier news; DoD industrial-base announcements |
| Copperhead FDA listing renewals | Pharma continuity | NDC/DMF listings beyond 2026 [S27] |
| Further carve-out acquisitions or divestitures | Portfolio direction | Business Wire releases |
| Leadership/succession announcements | Governance risk | Press releases |
| Organotin regulatory developments (EU/US) | Demand risk | REACH/TSCA actions |
Concluding analyst verdict
PMC Group, Inc. is a durable but opaque founder-owned consolidator of niche specialty chemicals that has, over three decades, turned non-core castoffs from global majors into a nine-unit portfolio spanning organotin additives, bio-based amides, process aids, rubber chemicals, pharmaceutical CDMO capacity and defense energetics. Its most defensible assets are clear: a large global share of organotin PVC stabilizers built through the 2012–2013 Arkema and Dow transactions, heritage additive brands such as FASCAT®, Armoslip® and Kemamide®, the hazardous-chemistry and cGMP capabilities of PMC Isochem, and Copperhead's position as the sole US manufacturer of FDA-approved nitroglycerin with recognized standing in the defense supply chain.
The 2024–2026 period marks a clear pivot from expansion to rationalization. Management exited commodity fatty acids, closed the 172-person Memphis plant, shifted amide growth to South Korea, and imposed a 10–25% global price increase on organotins amid raw-material, freight and geopolitical cost pressure. These are rational responses to a soft 2025 market – one in which listed peer SONGWON saw tin-intermediate prices decline and group sales fall nearly 3% – but they also reveal that parts of the portfolio were sub-economic.
The central analytical limitation is transparency. With no disclosed revenue, profitability, leverage or governance structure, any external party – lender, customer, acquirer or supplier – must underwrite PMC on asset quality and track record rather than financial evidence. Key-person risk around the founder is material.
Verdict: PMC is best viewed as a collection of strategically valuable niche assets held within a low-disclosure family structure. For counterparties, the group is commercially credible but requires direct financial due diligence. For potential acquirers, Copperhead and the organotin franchise are the crown jewels; for competitors, PMC's 2026 pricing move is a signal of supply discipline in organotins worth monitoring closely.
Unlock Company Financials
Unlock this company profile to view its financial data.
View Subscription PlansExecutive Leadership
Executive Leadership Team
| Name | Title (latest disclosed) | Tenure / prior roles disclosed |
|---|---|---|
Dr. Paritosh M. Chakrabarti | Founder and owner; Chairman/CEO (CEO title cited in third-party profile) | Founded PMC in 1994; author and philanthropist; founder of the Chakrabarti Foundation (1995) |
Debtosh Chakrabarti | President, PMC Group N.A., Inc. | Quoted as President on the Lanxess deal (2019), Organometallix expansion (2020) and Biogenix expansion (2024); quoted as President on Dow acquisition (2013) |
Dr. Raj Chakrabarti | President, PMC Group International, Inc. | VP & Chief Strategy Officer (Nov 2017) → Executive Vice President (Dec 2017) → President (by Feb 2021); led pharma acquisitions |
Patti Griggs | Director of Customer & Administrative Services; Assistant to the Chairman of the Board (2008); media contact for PMC Group International | Long-tenured (since at least 2008) |
Governance Overview
| Item | Status |
|---|---|
Board composition | Not publicly disclosed (a board of directors with a chairman existed as of 2008 [S5]) |
Chair/CEO separation | Not publicly disclosed; founder appears to hold both ownership control and top executive role |
Code of conduct | Published on website [S1] |
Commercial terms & conditions | Published on website [S1] |
Major Shareholders
| Holder | Stake |
|---|---|
Dr. Paritosh M. Chakrabarti | Owner (stake not quantified; described as owner of PMC Group) |
Institutional holders (top 10) | Not applicable – no public float |
Insider ownership | Effectively 100% insider/family-controlled (assessed) |
Competitive Landscape
Competitors by Segment
| Segment | Competitor | HQ | Ownership | Relevant revenue (verified) | Relative positioning vs PMC |
|---|---|---|---|---|---|
Organotin stabilizers / tin intermediates | SONGWON Industrial | South Korea | Listed (KRX) | FY2025 sales KRW 1,039,162M; Performance Chemicals division KRW 286,237M [S28] | Broader polymer-stabilizer portfolio; also active in tin intermediates; larger and more diversified than PMC's tin business |
Organotin & mixed-metal PVC stabilizers | Baerlocher | Germany | Private | — | Global leader in PVC stabilizers across chemistries |
Organotin & PVC additives | Galata Chemicals | USA | Private | — | Direct US organotin competitor |
PVC stabilizers | Reagens | Italy | Private | — | Strong in Ca/Zn and other stabilizers |
Organotin catalysts & tin chemicals | TIB Chemicals | Germany | Private | — | Direct competitor in tin catalysts |
Fatty amides / slip additives | Croda (Crodamide) | UK | Listed (LSE) | — | Larger, higher-margin specialty peer |
Fatty amides / oleochemical additives | Fine Organic Industries | India | Listed (NSE/BSE) | — | Low-cost Indian competitor in plastic additives |
Metallic stearates | Baerlocher; Faci; Peter Greven | Germany/Italy | Private | — | Scale players in stearates |
Defoamers / wax emulsions | BYK (Altana), Evonik, Michelman, Münzing, Elementis | Various | Mixed | — | Much larger additive formulators |
Rubber chemicals (India) | NOCIL | India | Listed (NSE/BSE) | FY2025 (Mar-25) revenue from operations INR 1,393 crore, down from INR 1,445 crore [S29] | India's largest rubber-chemicals maker; PMC's India unit is a much smaller niche player (assessed) |
Rubber chemicals (global) | Lanxess, Sunsine, Kumho Petrochemical | Various | Listed | — | Scale and cost leaders |
Pharma CDMO (small-molecule, hazardous chemistry) | Seqens, Axplora (ex-Novasep), Siegfried, Olon, Minakem | Europe | Mixed | — | Larger European CDMOs; PMC Isochem competes in phosgenation and niche APIs |
Generic APIs (India) | Numerous Indian API makers | India | Mixed | — | Highly competitive; fluoroquinolones commoditized |
Defense energetics (nitrate esters) | Government-owned/contractor-operated US ammunition plants and other primes' captive capacity | USA | Government/contractor | — | Copperhead is a specialized private-sector supplier |
Peer Comparison FY2025
| Metric | SONGWON (FY2025) | NOCIL (FY Mar-2025) |
|---|---|---|
Revenue | KRW 1,039,162M [S28] | INR 1,393 crore [S29] |
Revenue growth YoY | -2.9% [S28] | ≈-4% [S29] |
Gross margin | 13.7% [S28] | — |
Recent Developments
Dates are as reported.
Within the 18-month window
| Date | Event | Significance | Source |
|---|---|---|---|
| 9 Apr 2025 | PMC Isochem posts production operator vacancies (5-shift pattern) at Pithiviers, describing itself as ~250 staff on 3 sites with 50 years' experience in custom manufacturing of intermediates, excipients and APIs | Indicates ongoing French operations and hiring | [S23] |
| Aug 2025 | New corporate website assets published (logo, design) | Start of rebrand | [S1] |
| Nov 2025 | Website icon/brand assets updated | Rebrand continues | [S1] |
| Feb 2026 | New business-unit logos posted for all nine units | Brand architecture refresh | [S1] |
| Feb 2026 | PMC Biogenix files WARN notice with Tennessee Dept. of Labor for permanent closure of Memphis plant | Major footprint reduction; 172 jobs | [S16][S17] |
| 3 Mar 2026 | Daily Memphian reports closure of the facility on 26 April with 172 layoffs | Public disclosure of closure | [S16] |
| 4 Mar 2026 | Hoodline reports 122 of 172 workers are union-represented; Greater Memphis rapid-response team engaged; references 2022 safety incident | Labor and community impact | [S17] |
| 24 Apr 2026 | PMC Organometallix announces global price increase of 10–25% across all product lines effective 1 May 2026, citing raw materials, freight/logistics and the Iran-conflict geopolitical environment | Pricing power; cost inflation signal | [S19] |
| 26 Apr 2026 | Scheduled permanent closure of Memphis Pope Street plant | Completion of Biogenix US exit from Memphis | [S16][S18] |
| Mid-2026 | Targeted start of new Armoslip® supply from Gyeongju (+50% capacity) | Capacity ramp; completion not independently confirmed | [S12] |
| Jul–Aug 2026 | FDA NDC listings for Copperhead diluted nitroglycerin bulk ingredient active (data synced Jul/Aug 2026) | Confirms continuing pharma bulk supply | [S26] |
| Through 2026 | Copperhead DMF/NDC bulk listings: two powder listings ended 31 Dec 2025; another runs to 31 Dec 2026 | Routine regulatory listing lifecycle; monitor renewals | [S27] |
| Aug 2026 | New Copperhead logo added to PMC website | Copperhead brand integration | [S1] |
Context events (preceding window, last ~3 years)
| Date | Event | Significance | Source |
|---|---|---|---|
| 14 Mar 2023 | Copperhead receives Northrop Grumman 2022 Strategic Excellence Award | Defense supply-chain validation | [S33] |
| 14 Mar 2023 | PMC Group and Chakrabarti Foundation donate land/property to Ramakrishna Mission Belur Math | Founder philanthropy; ownership confirmed | [S14] |
| 21 Jun 2024 | PMC Biogenix announces Gyeongju expansion and Memphis restructuring | Strategic pivot in oleochemicals | [S12] |
| 2,022 | Memphis plant safety incident with fire response and air monitoring | EHS history | [S17] |



